enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $34.40.
A number of research firms recently issued reports on ENGN. UBS Group began coverage on enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Leerink Partnrs reissued an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Wells Fargo & Company started coverage on enGene in a research report on Monday, April 22nd. They set an “overweight” rating and a $30.00 price target for the company. Guggenheim started coverage on enGene in a research report on Monday, April 15th. They set a “buy” rating and a $34.00 price target for the company. Finally, Morgan Stanley started coverage on enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target for the company.
Get Our Latest Stock Analysis on ENGN
enGene Stock Performance
Insider Buying and Selling at enGene
In other news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75. Following the sale, the insider now directly owns 3,084,107 shares of the company’s stock, valued at $46,292,446.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Institutional Investors Weigh In On enGene
A number of hedge funds have recently added to or reduced their stakes in the business. Vivo Capital LLC bought a new stake in shares of enGene during the fourth quarter valued at approximately $6,264,000. Omega Fund Management LLC bought a new stake in shares of enGene during the fourth quarter valued at approximately $10,441,000. BVF Inc. IL bought a new stake in shares of enGene during the fourth quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new stake in shares of enGene during the fourth quarter valued at approximately $80,097,000. 64.16% of the stock is currently owned by institutional investors.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Articles
- Five stocks we like better than enGene
- 3 Best Fintech Stocks for a Portfolio Boost
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Are Penny Stocks a Good Fit for Your Portfolio?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.